Study guide
7.2 Systemic Autoimmune & Vasculitic Diseases
MRCPI in General Medicine Part I Written
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Strategy & Foundation
1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy
2 Chapter 2: Cardiology & Vascular Medicine
2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases
3 Chapter 3: Respiratory Medicine
3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
4 Chapter 4: Gastroenterology & Hepatology
4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition
5 Chapter 5: Nephrology & Acid-Base Disorders
5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders
6 Chapter 6: Endocrinology & Diabetes
6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes
7 Chapter 7: Rheumatology & Clinical Immunology
7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology
8 Chapter 8: Haematology & Medical Oncology
8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies
9 Chapter 9: Neurology & Dermatology
9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease
10 Chapter 10: Acute Medicine, Critical Care & Geriatrics
10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care
11 Chapter 11: Clinical Pharmacology & Therapeutics
11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety
12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics
12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics
7.2 Systemic Autoimmune & Vasculitic Diseases
Key Takeaways Explain This Topic AI
ANA positivity at ≥1:80 is the mandatory entry criterion for EULAR/ACR SLE classification; anti-dsDNA correlates dynamically with lupus nephritis flares, while anti-Smith is highly specific.
Antiphospholipid Syndrome requires 1 clinical criterion (thrombosis/pregnancy loss) plus 1 lab criterion (lupus anticoagulant, anti-β2-GPI, anti-cardiolipin) confirmed on 2 occasions ≥12 weeks apart.
Scleroderma Renal Crisis presents with malignant hypertension and AKI in diffuse systemic sclerosis; treat immediately with oral ACE inhibitors (Captopril) and STRICTLY avoid corticosteroids (>15 mg/day).
Dermatomyositis presents with proximal muscle weakness, elevated CK (10–50x), Gottron papules, and heliotrope rash; age-appropriate malignancy screening is mandatory due to a 3–6 fold risk of adenocarcinoma.
Granulomatosis with Polyangiitis (GPA) features the classic upper airway, lung (cavitating nodules), and renal (pauci-immune RPGN) triad, serologically driven by c-ANCA / anti-PR3 antibodies.
Last updated: July 2026
7.2 Systemic Autoimmune & Vasculitic Diseases
Systemic autoimmune connective tissue diseases and vasculitides present multi-organ pathology requiring precise serological interpretation, prompt immunosuppressive escalation, and vigilance for life-threatening complications.
- Systemic Lupus Erythematosus (SLE)
- Diagnostic Criteria & Entry Standard
Under the 2019 EULAR / ACR Classification Criteria , an Antinuclear Antibody (ANA) titer of ≥1:80 on HEp-2 cells is the mandatory entry criterion . Once satisfied, clinical and immunological domains are scored. A total score of ≥10 points classifies SLE.
Autoantibody Panel & Clinical Correlations
ANA: Sensitivity >95%. Highly sensitive screening tool, but low specificity.
Anti-double-stranded DNA (anti-dsDNA): Sensitivity ~60–70%, Specificity ~95% . Levels correlate dynamically with disease activity and predict active Lupus Nephritis flares.
Anti-Smith (anti-Sm): Sensitivity ~20–30%, Specificity ~99% . Pathognomonic for SLE; levels do not fluctuate with disease activity.
Anti-Ro (SSA) & Anti-La (SSB): Associated with Subacute Cutaneous Lupus (SCLE) , Sjögren syndrome , and transplacental IgG passage causing Neonatal Lupus and congenital complete heart block.
Anti-ribosomal P: Specific for Neuropsychiatric Lupus (lupus psychosis, severe depression).
Anti-U1-RNP: High titers are characteristic of Mixed Connective Tissue Disease (MCTD) (overlap of SLE, systemic sclerosis, and polymyositis).
Serum Complements (C3, C4): Hypocomplementemia indicates active classical complement pathway consumption during active lupus flares.
Lupus Nephritis Staging & Management
Lupus nephritis affects up to 50% of SLE patients. Renal biopsy is essential:
Class I: Minimal mesangial lupus nephritis.
Class II: Mesangial proliferative lupus nephritis.
Class III: Focal lupus nephritis (<50% of glomeruli involved).
Class IV (Diffuse Proliferative): Most common and severe pattern (>50% glomeruli involved; wire-loop lesions on light microscopy). Requires immediate induction therapy with high-dose corticosteroids PLUS Mycophenolate Mofetil or IV Cyclophosphamide .
Class V: Membranous lupus nephritis (severe nephrotic-range proteinuria).
Class VI: Advanced sclerotic lupus nephritis (>90% sclerotic glomeruli).
Universal Rule: Every SLE patient without contraindications MUST receive long-term Hydroxychloroquine (200–400 mg/day, capped at <5 mg/kg actual body weight to prevent retinal toxicity), which reduces flares, organ damage accumulation, thrombotic risk, and overall mortality.
- Antiphospholipid Syndrome (APS)
- Diagnostic Sydney Criteria
Diagnosis requires at least 1 Clinical Criterion AND 1 Laboratory Criterion :
Clinical Criteria:
Vascular Thrombosis: ≥1 episode of arterial, venous, or small vessel thrombosis confirmed by imaging or histopathology.
Pregnancy Morbidity:
- ≥3 unexplained consecutive spontaneous abortions <10th week of gestation, OR
- ≥1 unexplained fetal loss ≥10th week of gestation (morphologically normal fetus), OR
≥1 premature birth <34th week of gestation due to eclampsia, severe pre-eclampsia, or placental insufficiency.
Laboratory Criteria (Confirmed on ≥2 occasions at least 12 weeks apart):
Lupus Anticoagulant (LA): Prolonged phospholipid-dependent coagulation assay (APTT, dRVVT) that fails to correct with 1:1 normal plasma mix, but corrects upon adding excess phospholipids.
Anti-β₂-Glycoprotein I antibodies (IgG or IgM >99th percentile).
Anti-Cardiolipin antibodies (IgG or IgM medium/high titer >40 GPL/MPL).
Catastrophic Antiphospholipid Syndrome (CAPS)
Rapidly fatal microvascular thrombosis leading to organ failure in ≥3 organ systems within <1 week. Emergency Management: High-dose IV Corticosteroids + Therapeutic Anticoagulation (Heparin) + Plasma Exchange + IVIG.
Anticoagulation Management Protocols
Primary Prevention (Asymptomatic positive antibodies): Low-dose Aspirin (75–100 mg daily).
Secondary Prevention (Post-Venous Thromboembolism): Lifelong Warfarin targeted to an INR of 2.0–3.0 .
Arterial Thrombosis or Recurrent Venous Events on Warfarin: Warfarin targeted to an INR of 3.0–4.0 or INR 2.0–3.0 plus low-dose Aspirin.
DOAC Warning: Direct Oral Anticoagulants (Rivaroxaban, Apixaban) are contraindicated in high-risk triple-positive APS due to significantly increased rates of arterial thrombotic events compared to Warfarin.
Pregnancy in APS: Warfarin is teratogenic. Switch immediately to Therapeutic LMWH plus Low-dose Aspirin .
- Systemic Sclerosis & Sjögren Syndrome
- Systemic Sclerosis (Scleroderma)
Autoimmune vasculopathy, immune activation, and excessive collagen deposition leading to skin fibrosis and visceral organ disease. Systemic Sclerosis Subtypes
- │
- ┌─────────────────────────┴─────────────────────────┐
- ▼ ▼
- [Limited Cutaneous (lcSSc)] [Diffuse Cutaneous (dcSSc)]
- Skin: Distal to elbows/knees, face • Skin: Proximal to elbows/knees, trunk
- CREST Syndrome features • Rapid onset skin thickening
- Autoantibody: Anti-Centromere (~70–80%) • Autoantibodies:
- Major Risk: Isolated Pulmonary Arterial - Anti-Scl-70 (Anti-topoisomerase I; ILD)
- Hypertension (PAH late in disease) - Anti-RNA Polymerase III (Renal Crisis)
CREST Acronym: Calcinosis cutis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias.
Scleroderma Renal Crisis (SRC): Abrupt onset of malignant hypertension, acute kidney injury, oliguria, and microangiopathic hemolytic anemia. Almost exclusively seen in diffuse systemic sclerosis (anti-RNA polymerase III positive).
Emergency Management: Immediate introduction of short-acting ACE Inhibitors (oral Captopril) titrated aggressively. Continue ACE inhibitor even if serum creatinine initially rises.
STEROID WARNING: Moderate-to-high dose corticosteroids ( Prednisolone >15 mg/day ) are strictly contraindicated in diffuse cutaneous systemic sclerosis as they directly precipitate Scleroderma Renal Crisis!
Sjögren Syndrome
Pathophysiology: Autoimmune lymphocytic infiltration and destruction of exocrine glands (lacrimal and salivary glands).
Clinical Presentation: Keratoconjunctivitis sicca (dry eyes), Xerostomia (dry mouth), bilateral parotid gland enlargement, and systemic features (arthralgia, fatigue, interstitial nephritis).
Diagnostic Evaluation:
Schirmer Test: Standardized filter paper placed in lower conjunctival sac; ≤5 mm wetting in 5 minutes indicates severe tear deficiency.
Autoantibodies: Anti-Ro/SSA (70%) and Anti-La/SSB (50%).
Minor Salivary Gland Biopsy: Focal lymphocytic sialadenitis with a Focus Score ≥1 focus per 4 mm² (a focus = collection of ≥50 lymphocytes).
Malignancy Complication: Patients have a 15- to 20-fold increased risk of B-cell Non-Hodgkin Lymphoma (specifically MALT lymphoma of the parotid gland). Suspect lymphoma if persistent asymmetric parotid swelling, palpable purpura, monoclonal gammopathy, or sudden drop in C4 levels occurs.
- Inflammatory Myopathies
- Polymyositis (PM) vs. Dermatomyositis (DM)
Symmetrical, subacute, progressive proximal muscle weakness (shoulder girdle, hip flexors—difficulty rising from a chair, climbing stairs, or combing hair). Sensory examination is normal.
Laboratory Profile: Markedly elevated Creatine Kinase (CK, 10–50x upper limit of normal), AST, ALT, LDH, and Aldolase.
Electromyography (EMG): Triad of short, small-amplitude polyphasic motor unit action potentials, fibrillations, and complex repetitive discharges.
Muscle Biopsy Distinctions:
Polymyositis: Endomysial inflammation with CD8+ T-lymphocytes invading non-necrotic muscle fibers.
Dermatomyositis: Perimysial and perivascular inflammation with CD4+ T-lymphocytes and B-cells, accompanied by characteristic perifascicular atrophy .
Dermatomyositis Cutaneous Signatures
Gottron Papules: Erythematous/violaceous flat papules over the dorsal aspect of MCP and PIP joints (pathognomonic).
Heliotrope Rash: Violaceous periorbital edema affecting upper eyelids.
Shawl Sign & V-Sign: Erythematous rash across shoulders/upper back (shawl) or anterior neck/chest (V-sign).
Mechanic's Hands: Hyperkeratosis, scaling, and painful fissuring along the lateral aspects of fingers.
Myositis Autoantibodies & Malignancy Risk
Anti-Jo-1 (Histidyl-tRNA synthetase): Associated with Antisynthetase Syndrome (myositis, severe Interstitial Lung Disease, Raynaud phenomenon, fever, mechanic's hands).
Anti-Mi-2: Classic dermatomyositis with prominent skin features and favorable response to corticosteroids.
Anti-MDA5: Amyopathic dermatomyositis with rapidly progressive ILD and palmar cutaneous ulcerations.
Malignancy Screening: Dermatomyositis carries a 3- to 6-fold increased risk of underlying adenocarcinoma (ovarian, breast, lung, gastric, nasopharyngeal carcinoma). Mandatory age-appropriate cancer screening (CT chest/abdomen/pelvis, mammography, pelvic US, endoscopy) is required at diagnosis.
Inclusion Body Myositis (IBM)
Epidemiology: Most common inflammatory myopathy in patients >50 years old (male predominance).
Clinical Pattern: Insidious, asymmetrical distal and proximal weakness targeting wrist flexors, finger flexors (deep flexors), and quadriceps femoris. Dysphagia occurs in 50%.
Biopsy: Rimmed vacuoles containing ubiquitin and beta-amyloid inclusions.
Treatment: Remarkably resistant to corticosteroids and immunosuppressive therapy.
Systemic Vasculitis Classification & Serology Matrix
Vasculitides are categorized by the Chapel Hill Consensus Conference based on predominant vessel size:
Vessel Size Vasculitis Entity Key Clinical Features & Pathognomonic Serology First-Line Therapy
Large Vessel Giant Cell Arteritis (GCA) Age >50, temporal headache, jaw claudication, scalp tenderness, amaurosis fugax, ESR >50 mm/h. Temporal Artery Biopsy: Granulomatous panarteritis. Immediate High-Dose Corticosteroids (Oral Prednisolone 40–60 mg/d; IV Methylprednisolone 1 g/d if visual loss) + Tocilizumab
Large Vessel Takayasu Arteritis Females <40, "pulseless disease", limb claudication, blood pressure asymmetry (>10 mmHg between arms), subclavian bruits. Angiography: Aortic arch stenosis. High-dose Corticosteroids + Methotrexate / Tocilizumab
Medium Vessel Polyarteritis Nodosa (PAN) Necrotizing vasculitis, hypertension, mononeuritis multiplex, livedo reticularis, testicular pain. Sparing lungs! Linked with Hepatitis B Virus (HBV) . Corticosteroids + Cyclophosphamide; Antiviral therapy if HBV-positive
Medium Vessel Kawasaki Disease Children <5 years, fever >5 days, strawberry tongue, conjunctivitis, cervical lymphadenopathy, desquamation. Risk of coronary artery aneurysms . High-dose IVIG (2 g/kg) + High-dose Aspirin
Small Vessel (ANCA) Granulomatosis with Polyangiitis (GPA) Triad: Upper airway (sinusitis, saddle nose), Lower airway (cavitating pulmonary nodules), Renal (pauci-immune RPGN). c-ANCA / Anti-PR3 (90%) . Induction: Cyclophosphamide or Rituximab + Corticosteroids
Small Vessel (ANCA) Microscopic Polyangiitis (MPA) Non-granulomatous vasculitis, pulmonary capillaritis (alveolar hemorrhage) + pauci-immune RPGN. p-ANCA / Anti-MPO (80%) . Induction: Cyclophosphamide or Rituximab + Corticosteroids
Small Vessel (ANCA) Eosinophilic GPA (EGPA) Severe asthma, eosinophilia (>1.5 × 10⁹/L or >10%), pulmonary infiltrates, mononeuritis multiplex. p-ANCA / Anti-MPO (40–50%) . Corticosteroids + Mepolizumab (Anti-IL-5) or Cyclophosphamide
Small Vessel (Immune) IgA Vasculitis (HSP) Children/young adults, palpable purpura over buttocks/lower limbs, arthralgia, abdominal colic, IgA glomerulonephritis. Supportive care; short-course corticosteroids for severe abdominal pain
Small Vessel (Immune) Cryoglobulinemic Vasculitis Essential mixed cryoglobulinemia (Type II/III). Strongly associated with Hepatitis C Virus (HCV) . Low C4, purpura, arthralgia, neuropathy. Direct-Acting Antivirals (DAAs) for HCV + Rituximab / Plasma Exchange